Marie-pierre P. Moreau-Moles

Angers, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients.

Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients.

Journal: Haematologica
Published: November 08, 2022

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.

Journal: Blood
Published: October 28, 2021

Impact of High-Dose Methotrexate on the Outcome of Patients with Diffuse Large B-Cell Lymphoma and Skeletal Involvement.

Impact of High-Dose Methotrexate on the Outcome of Patients with Diffuse Large B-Cell Lymphoma and Skeletal Involvement.

Journal: Cancers
Published: May 18, 2021

Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network.

Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network.

Journal: Neurology
Published: March 26, 2021

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.

Journal: Blood advances
Published: March 18, 2021

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.

Journal: Leukemia
Published: November 18, 2020

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

Journal: Blood advances
Published: July 29, 2020

Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma.

Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma.

Journal: Radiology
Published: April 15, 2020

Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab.

Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: June 25, 2019

Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.

Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.

Journal: Neurology
Published: April 12, 2019

Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.

Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.

Journal: European journal of cancer (Oxford, England : 1990)
Published: February 12, 2019

Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma.

Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma.

Journal: Annals of hematology
Published: May 27, 2018
Showing 1-12 of 15

Last Updated: 09/26/2026